Genprex, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Genprex, Inc. (GNPX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $111904.51 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-06-30 was $111904.51.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $4280.00, a 70.18% increase from fiscal 2024.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $2515.00, a 2308.54% increase from fiscal 2023.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $104.42, a 2.49% increase from fiscal 2022.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $101.88, a 3296.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $111904.51 10-Q · filed 2026-08-14 | $111904.51 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | $0.00 10-Q · filed 2026-08-14 | ||||||
| 2025-12-31 | $4280.00 10-K · filed 2026-03-30 | ||||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | $4280.00 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-14 | $85.60 10-Q · filed 2025-08-14 | |||||
| 2025-03-31 | $94160.00 10-Q · filed 2026-08-14 | $85.60 10-Q · filed 2025-05-12 | |||||
| 2024-12-31 | $2515.00 10-K · filed 2026-03-30 | $50.86 10-K · filed 2025-04-01 | |||||
| 2024-09-30 | $2766.67 10-Q · filed 2025-11-14 | $55.25 10-Q · filed 2024-11-13 | $2497.07 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | $2734.78 10-Q · filed 2025-11-14 | $14.75 10-Q · filed 2024-08-09 | $49.01 10-Q · filed 2025-08-14 | $32.40 10-Q · filed 2024-08-09 | |||
| 2024-03-31 | $1620.00 10-Q · filed 2025-11-14 | $32.40 10-Q · filed 2024-05-15 | |||||
| 2023-12-31 | $104.42 10-K · filed 2025-04-01 | ||||||
| 2023-09-30 | $124.64 10-Q · filed 2024-11-13 | $3.12 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | $0.00 10-Q · filed 2024-11-13 | ||||||
| 2023-03-31 | $0.00 10-Q · filed 2024-11-13 | ||||||
| 2022-12-31 | $101.88 10-K · filed 2024-04-01 | $2.55 10-K · filed 2023-03-31 | |||||
| 2022-09-30 | $2.74 10-Q · filed 2023-11-14 | $2.55 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $2.00 10-Q · filed 2023-08-21 | ||||||
| 2022-03-31 | $2.00 10-Q · filed 2023-11-14 | ||||||
| 2021-12-31 | $3.00 10-K · filed 2023-03-31 | ||||||
| 2021-09-30 | $7.22 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | $7.22 10-Q · filed 2021-08-13 | ||||||
| 2021-03-31 | $7.22 10-Q · filed 2021-05-17 | ||||||
| 2020-12-31 | $8.31 10-K · filed 2022-03-30 | ||||||
| 2020-09-30 | $9.80 10-Q · filed 2020-11-12 | ||||||
| 2020-06-30 | $9.80 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |